Nucana shares surge 20.53% premarket after Q3 financial turnaround and clinical progress boost investor confidence.

Nucana surged 20.53% in premarket trading following the release of its third-quarter 2025 financial results and positive updates on its clinical pipeline. The company reported a significant reduction in net losses to £0.281 million from £4.51 million year-over-year, alongside £25.2 million in cash reserves, extending its financial runway through 2029. Strong liquidity and progress in its lead candidate, NUC-7738, including combination therapy data and PD-1 inhibitor trials, bolstered investor confidence. Additionally, regulatory discussions with the FDA and a key patent in China reinforced its competitive positioning. Despite a 2.29% decline in Friday’s closing, the premarket rally reflects optimism over the firm’s financial stability and advancing clinical milestones.